

# Lemon Tree Hotels

Estimate change	↔
TP change	↔
Rating change	↔

## Stock Info

Bloomberg	LEMONTRE IN
Equity Shares (m)	792
M.Cap.(INRb)/(USD\$)	105.3 / 1.2
52-Week Range (INR)	181 / 111
1, 6, 12 Rel. Per (%)	-12/-14/-14
12M Avg Val (INR M)	534
Free float (%)	77.7

## Financials & Valuations (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	14.5	16.7	17.9
EBITDA	7.0	8.5	9.3
PAT	2.66	3.42	4.05
EBITDA (%)	48.3	51.0	51.7
EPS (INR)	3.4	4.3	5.1
EBITDA Gr. (%)	35.1	28.7	18.5
BV/Sh. (INR)	17.7	22.1	27.2

## Ratios

Net D/E	1.0	0.5	0.2
RoE (%)	20.7	21.7	20.8
RoCE (%)	13.4	17.2	19.4

## Valuations

P/E (x)	39.6	30.8	26.0
EV/EBITDA (x)	17.9	14.4	12.9
FCF Yield (%)	4.7	6.1	6.4

## Shareholding Pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	22.3	22.3	22.8
DII	19.5	19.7	20.8
FII	21.6	21.5	20.1
Others	36.7	36.5	36.4

**CMP: INR133**

**TP: INR200 (+51%)**

**Buy**

## ARR growth offsets occupancy pressure

### Operating performance in line with estimates

- Lemon Tree Hotels (LEMONTRE) reported healthy revenue growth of 14% YoY in 3QFY26, led by 34% YoY growth in FnB revenue and 7% YoY growth in room revenue. Average room rate (ARR) grew 11% YoY to INR7,487, while occupancy rate (OR) declined 80bp YoY to 73.4%.
- LEMONTRE maintained industry-leading EBITDA margins at 50.4%, which were, however, impacted by higher investments in renovations and technology and the GST impact, leading to a 150bp YoY contraction.
- The industry witnessed a muted start to 4QFY26 due to a soft January, while February registered strong demand, with March expected to sustain a similar momentum.
- We largely maintain our FY26/FY27/FY28 EBITDA estimates and reiterate our **BUY** rating on the stock with our SoTP-based **TP of INR200** for FY28.

### Margin impacted by higher renovation opex and investment in technology

- Revenue grew 14% YoY to INR4b (in line). OR declined 82bp YoY to 74.2%. ARR increased 11% YoY to INR7,487. Management fees grew 24% YoY to INR229m.
- EBITDA grew 11% YoY to INR2b (est in line). EBITDA margin contracted 150bp YoY to 50.4% (est. 49.5%). Adj. PAT increased 38% YoY to INR862m (est. INR771m).
- During the quarter, LEMONTRE signed 17 new management and franchise contracts, which added 1,855 new rooms to its pipeline, and operationalized nine hotels, which added 816 rooms to its portfolio.
- As of 31<sup>st</sup> Dec'25, the total operational inventory comprised 130 hotels with 11,772 rooms, and the pipeline included 129 hotels with 10,170 rooms.
- In 9MFY26, revenue/EBITDA/adj. PAT grew 13%/11%/42% to INR10.3b/INR4.6b/INR1.6b.

### Highlights from the management commentary

- **Aurika:** The company is strengthening the Aurika portfolio with planned launches across New Delhi, Shimla, and Varanasi. Design and approval work have been initiated for the Aurika project in Nehru Place, while two blocks of Aurika Shimla are scheduled to open by 2QCY26. The 47-room heritage Aurika hotel in Varanasi is expected to command an ARR nearly 3x that of other Aurika properties.
- **Key city performance:** Hyderabad delivered strong ARR growth (up 25% YoY), led by renovation and better demand. ARR in Pune grew 8% YoY, driven by renovation at Pimpri and improving conditions in Hinjewadi. Performance in Gurgaon remained subdued due to the absence of last year's large corporate blocks and weaker Red Fox performance, which led OR to decline to 69% from 74%. Mumbai/Delhi ARR grew 4%/10% YoY to INR9,391/INR8,748, and the OR grew 220bp/40bp to 79%/84%.
- **Fee income:** Fee income remained broadly stable during the year, despite the addition of 1,600 rooms in 9MFY26 (800 in 1H and 800 in 3Q). These additions are expected to start contributing meaningfully after roughly one year of operations.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst: **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### Valuation and view

- LEMONTRE is expected to maintain a healthy growth momentum going forward, led by: 1) the improving ARR of Aurika Mumbai, 2) accelerated growth in management contracts (pipeline of ~9,364 rooms), 3) the timely completion of the portfolio's renovation (by mid of FY27), leading to an improved OR, ARR, and EBITDA margin for the company, 4) rebranding of existing hotels, and 5) expansion of the Aurika portfolio.
- We expect LEMONTRE to post a CAGR of 12%/13%/27% in revenue/EBITDA/adj. PAT over FY25-28, with RoCE improving to ~19.4% by FY28 from ~11.7% in FY25. We reiterate our BUY rating on the stock with our SoTP-based TP of INR200 for FY28.

### Consolidated Quarterly Performance


Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
<b>Gross Sales</b>	<b>2,680</b>	<b>2,844</b>	<b>3,552</b>	<b>3,785</b>	<b>3,158</b>	<b>3,063</b>	<b>4,061</b>	<b>4,242</b>	<b>12,861</b>	<b>14,523</b>	<b>3,946</b>	<b>3</b>
YoY Change (%)	20.6	25.2	23.0	15.6	17.8	7.7	14.3	12.1	20.7	12.9	11.1	
Total Expenditure	1,530	1,536	1,710	1,744	1,753	1,756	2,014	1,990	6,520	7,512	1,992	
<b>EBITDA</b>	<b>1,151</b>	<b>1,307</b>	<b>1,842</b>	<b>2,041</b>	<b>1,405</b>	<b>1,307</b>	<b>2,047</b>	<b>2,252</b>	<b>6,341</b>	<b>7,011</b>	<b>1,954</b>	<b>5</b>
Margins (%)	42.9	46.0	51.9	53.9	44.5	42.7	50.4	53.1	49.3	48.3	49.5	
Depreciation	346	348	351	349	342	343	348	362	1,393	1,395	353	
Interest	518	513	503	472	447	423	414	362	2,007	1,647	400	
Other Income	4	5	6	9	16	17	17	11	23	61	14	
<b>PBT before EO expense</b>	<b>291</b>	<b>451</b>	<b>994</b>	<b>1,229</b>	<b>633</b>	<b>558</b>	<b>1,302</b>	<b>1,539</b>	<b>2,965</b>	<b>4,031</b>	<b>1,215</b>	
Extra-Ord expense	0	0	0	0	0	0	313	0	0	313	0	
<b>PBT</b>	<b>291</b>	<b>451</b>	<b>994</b>	<b>1,229</b>	<b>633</b>	<b>558</b>	<b>988</b>	<b>1,539</b>	<b>2,965</b>	<b>3,718</b>	<b>1,215</b>	
Tax	91	102	197	141	148	139	170	225	531	682	243	
Rate (%)	31.2	22.7	19.8	11.5	23.3	24.9	17.2	14.6	17.9	18.3	20.0	
MI & P/L of Asso. Cos.	2	52	173	241	102	73	191	249	468	615	201	
<b>Reported PAT</b>	<b>198</b>	<b>296</b>	<b>625</b>	<b>846</b>	<b>383</b>	<b>346</b>	<b>627</b>	<b>1,064</b>	<b>1,966</b>	<b>2,420</b>	<b>771</b>	
<b>Adj PAT</b>	<b>198</b>	<b>296</b>	<b>625</b>	<b>846</b>	<b>383</b>	<b>346</b>	<b>862</b>	<b>1,064</b>	<b>1,966</b>	<b>2,655</b>	<b>771</b>	<b>12</b>
YoY Change (%)	-15.6	30.9	76.5	26.3	93.5	16.7	37.9	25.7	32.4	35.1	23.3	
Margins (%)	7.4	10.4	17.6	22.4	12.1	11.3	21.2	25.1	15.3	18.3	19.5	

### Key Performance Indicators

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Occupancy (%)	66.6	68.4	74.2	77.6	72.5	69.8	73.4	76.7	73.0	73.3
ARR (INR)	5,686	5,902	6,763	7,042	6,236	6,247	7,487	7,607	6,819	7,445
Change (%)	8.6	12.0	6.8	6.6	9.7	5.8	10.7	8.0	8.4	9.2
RevPAR (INR)	3,787	4,035	5,018	5,465	4,521	4,360	5,495	5,836	4,980	5,455
Change (%)	3.0	6.9	20.2	14.9	19.4	8.1	9.5	6.8		
<b>Cost Break-up</b>										
F&B Cost (% of sales)	6.1	6.0	5.5	6.1	6.3	6.5	5.7	6.0	5.9	6.1
Staff Cost (% of sales)	18.9	19.1	15.9	15.1	18.4	19.1	14.6	15.6	17.0	16.7
Power and fuel (% of sales)	8.7	8.0	6.0	5.3	6.9	7.4	5.0	6.3	6.8	6.3
Other Cost (% of sales)	23.3	20.9	20.7	19.6	23.9	24.3	24.3	19.0	21.0	22.7
Gross Margins (%)	93.9	94.0	94.5	93.9	93.7	93.5	94.3	94.0	94.1	93.9
EBITDA Margins (%)	42.9	46.0	51.9	53.9	44.5	42.7	50.4	53.1	49.3	48.3
EBIT Margins (%)	30.0	33.7	42.0	44.7	33.7	31.5	41.8	44.6	38.5	38.7


**Key exhibits**

**Exhibit 1: Consolidated revenue trend**




Source: Company, MOFSL

**Exhibit 2: Consolidated EBITDA trend**




Source: Company, MOFSL

**Exhibit 3: Consolidated adjusted PAT trend**




Source: Company, MOFSL

**Exhibit 4: ARR trend**




Source: Company, MOFSL

**Exhibit 5: Occupancy trend**



Source: Company, MOFSL

**Exhibit 6: RevPAR trend**



Source: Company, MOFSL

**Exhibit 7: Portfolio breakup as of 31<sup>st</sup> Dec'25 – operational**

Operational portfolio	Owned		Leased		Managed/ Franchised		Total	
	Hotels	Rooms	Hotels	Rooms	Hotels	Rooms	Hotels	Rooms
Aurika	2	808	0	0	0	0	2	808
Lemon Tree Premier	7	1,442	2	161	14	1,364	23	2,967
Lemon Tree Hotels	14	1,448	4	321	55	3,437	73	5,206
Red Fox Hotels	4	552	1	91	4	360	9	1,003
Keys Prima	0	0	0	0	3	130	3	130
Keys Select	7	936	0	0	5	354	12	1,290
Keys Lite	0	0	0	0	8	368	8	368
<b>Total</b>	<b>34</b>	<b>5,186</b>	<b>7</b>	<b>573</b>	<b>89</b>	<b>6,013</b>	<b>130</b>	<b>11,772</b>

Source: Company, MOFSL

**Exhibit 8: Portfolio breakup as of 31<sup>st</sup> Dec'25 – pipeline**

In pipeline	Owned		Leased		Public Private Partnership		Managed/Franchised		Total	
	Hotels	Rooms	Hotels	Rooms	Hotels	Rooms	Hotels	Rooms	Hotels	Rooms
Aurika	2	641	0	0	1	165	4	499	7	1,255
Lemon Tree Premier	0	0	0	0	0	0	11	1,136	11	1,136
Lemon Tree Hotels	0	0	0	0	0	0	69	5,481	69	5,481
Red Fox Hotels	0	0	0	0	0	0	1	50	1	50
Keys Prima	0	0	0	0	0	0	6	435	6	435
Keys Select	0	0	0	0	0	0	22	1,230	22	1,230
Keys Lite	0	0	0	0	0	0	13	533	13	533
<b>Total</b>	<b>2</b>	<b>641</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>165</b>	<b>126</b>	<b>9,364</b>	<b>129</b>	<b>10,120</b>

Source: Company, MOFSL

**Exhibit 9: Brand-wise operating performance trend**

	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
<b>Lemon Tree Premier</b>									
Occupancy (%)	77.0	81.0	79.0	79.0	81.0	83.0	81.0	80.0	81.0
ARR (INR)	7,437	7,565	6,558	6,802	7,852	8,156	7,132	7,142	8,506
Hotel level EBITDAR/room (INR m)	0.35	0.42	0.32	0.35	0.44	0.48	0.37	0.37	0.47
Hotel level EBITDAR Margin (%)	55.0	60.0	53.0	56.0	60.0	62.0	57.0	56.0	60.0
<b>Lemon Tree Hotels</b>									
Occupancy (%)	71.0	74.0	72.0	73.0	75.0	78.0	73.0	67.0	73.0
ARR (INR)	5,935	6,036	5,299	5,425	6,083	6,171	5,693	5,695	7,081
Hotel level EBITDAR/room (INR m)	0.25	0.25	0.20	0.24	0.28	0.27	0.23	0.19	0.31
Hotel level EBITDAR Margin (%)	50.0	50.0	43.0	50.0	52.0	50.0	47.0	44.0	52.0
<b>Red Fox Hotels</b>									
Occupancy (%)	73.0	76.0	64.0	70.0	78.0	80.0	67.0	65.0	70.0
ARR (INR)	4,746	4,796	4,214	4,458	5,144	5,457	4,873	4,824	5,016
Hotel level EBITDAR/room (INR m)	0.19	0.21	0.13	0.17	0.25	0.26	0.17	0.16	0.19
Hotel level EBITDAR Margin (%)	54.0	58.0	46.0	51.0	60.0	59.0	52.0	50.0	52.0
<b>Aurika</b>									
Occupancy (%)	42.0	66.0	46.0	50.0	71.0	83.0	72.0	71.0	74.0
ARR (INR)	10,743	10,553	9,061	9,491	10,457	10,566	9,118	8,806	10,984
Hotel level EBITDAR/room (INR m)	0.29	0.56	0.27	0.32	0.63	0.78	0.49	0.47	0.72
Hotel level EBITDAR Margin (%)	55.0	64.0	49.0	53.0	64.0	68.0	58.0	58.0	65.0

EBITDAR – Earnings before interest, taxes, depreciation, amortization, and rent

Source: Company, MOFSL

**Exhibit 10: Operational performance by regions**

Parameters by region (rooms)	Occupancy (%)		Change YoY* (bps)	ARR		Change YoY (%)
	3QFY26	3QFY25		3QFY26	3QFY25	
Delhi (636)	84	84	38	8,748	7,949	10
Gurugram (529)	69	74	-569	6,542	6,146	6
Hyderabad (663)	60	65	-355	9,113	7,298	25
Bengaluru (874)	60	65	-460	6,183	5,023	23
Mumbai (972)	79	76	223	9,391	9,052	4
Pune (426)	77	73	475	6,205	5,762	8
Rest of India (1,659)	72	732	15	6,230	5,862	6

Source: Company, MOFSL



## Highlights from the management commentary

### Operating performance

- The margin decline was largely driven by higher spending on renovation, technology upgrades, and GST-related costs. These investments accounted for 6.4% of revenue in the quarter. However, all three expense heads are expected to moderate to ~3.6% of revenue by FY28, supporting a meaningful expansion in EBITDA margins.
- The GST change alone accounted for 1.8% of revenue in what is typically a seasonally strong quarter. For the full-year FY27, this impact is expected to average around 2%, before easing to approximately 1.7% in FY28.
- The company incurred a one-off exceptional expense of INR313m related to the Labor Code impact, ex-gratia payments to employees, and a property tax settlement for its properties in New Delhi.
- RevPAR growth was impacted by a weak quarter in Gurgaon, where the region saw negative RevPAR momentum.
- In Mumbai, the company is prioritizing occupancy improvement first, following which it plans to drive rate-led growth.

### Aurika

- The company has initiated the design and approval process for its upcoming Aurika project at Nehru Place, which is expected to be completed over the next 3-3.5 years.
- It plans to open two out of three blocks of Aurika, Shimla, by 2Q 2026 to capture the increased demand during the summer season.
- In January, Lemon Tree Hotels signed a license deed for a 47-room heritage Aurika hotel in Varanasi, located directly on the ghat adjoining the Ganges River. Its prime riverfront location, coupled with Varanasi's year-round demand, is expected to support exceptionally high rates. Management expects ARR to be nearly 3x that of other Aurika properties.
- Material ARR growth expected going ahead in Mumbai Aurika.
- Aurika Shillong is scheduled to commence operations in 3QCY27. The total project cost is estimated at ~INR2b. The company can fund 70% of this through borrowings at an interest rate of 5% lower than its normal cost of debt, effectively borrowing INR1.4b at ~3%-2.5%. Additionally, the project is eligible for a GST retention benefit for the next 9 to 15 years, significantly enhancing project returns.
- In the Shillong market, the upcoming Aurika property will primarily compete with Taj Hotels and Marriott International. The property is strategically located

directly opposite the Chief Minister’s residence, giving it a strong visibility and positioning advantage.

### Fee income

- Fee income did not decline materially this year despite the addition of 1,600 rooms to the portfolio.
- The company added 800 rooms in 1H and another 800 rooms in 2H. Since fee income becomes meaningful only once new hotels stabilize, these additions are expected to start contributing meaningfully after roughly one year of operations.

### Outlook

- 4QFY26 is shaping up to be strong. While it began on a slower note, February has turned highly positive across companies, and March also appears to be excellent. Overall, 4Q is expected to outperform 3Q.
- Gurgaon remains a work in progress, as the company still needs to replace the large group business it had in 3Q and 4Q last year. As a result, the Lemon Tree and Red Fox portfolios continue to underperform meaningfully vs last year.
- The existing portfolio is expected to deliver ~15% revenue growth in the long run.

### Renovations and rebranding

- Instead of refurbishing the entire older portfolio, the company is selectively renovating hotels where there is strong potential to reprice meaningfully based on product upgrades.
- The Red Fox Hotel, New Delhi, was rebranded as a Lemon Tree property, resulting in a significant increase in ADR.
- A similar rebranding is planned for Red Fox Hyderabad, which is well located and has large rooms. Following renovation, it is expected to be rebranded as a Lemon Tree Hotel by October this year.
- The company has already rebranded Lemon Tree Keys Select into Keys Prima in Pimpri-Chinchwad, and it also plans to rebrand Keys Whitefield into Keys Prima, which aligns with the Premier positioning.
- The company is evaluating converting Lemon Tree LLP, a small but attractively located hotel outside Kochi, into an Aurika property—though this transition is not expected in the near term.

### Other key highlights

- Around 65% of the portfolio identified for renovation has already been completed, and at any given time, roughly 800 rooms remain closed due to ongoing refurbishment.
- In Gurgaon, large corporate blocks seen in Sector 60 last year did not materialize this year, and performance of the Red Fox brand was notably weaker.
- All ongoing technology investments are being pursued with a clear monetization roadmap. These initiatives began in FY25, will continue over the next 4–5 years, and are expected to become a progressively smaller share of revenue as they scale.
- In Pune, growth has been strong: Keys Prima delivered 25-30% RevPAR growth, while Lemon Tree Premier has stabilized. The Hinjewadi micro-market, which was high-performing when the hotel opened 20 years ago, had become

oversupplied, but the supply is now being absorbed, leading to improved market dynamics.

- Earlier, hotels were not designed to accommodate large MICE formats, but the company is now integrating MICE-friendly design into new properties to align with evolving demand trends.
- The company also plans to expand its presence in Dubai, strengthening its international footprint.

### Valuation and view

- LEMONTRE is expected to maintain a healthy growth momentum going forward, led by: 1) the improving ARR of Aurika Mumbai, 2) accelerated growth in management contracts (pipeline of ~9,364 rooms), 3) the timely completion of the portfolio’s renovation (by mid of FY27), leading to an improved OR, ARR, and EBITDA margin for the company, 4) rebranding of existing hotels, and 5) expansion of the Aurika portfolio.
- We expect LEMONTRE to post a CAGR of 12%/13%/27% in revenue/EBITDA/adj. PAT over FY25-28, with RoCE improving to ~19.4% by FY28 from ~11.7% in FY25. We reiterate our BUY rating on the stock with our SoTP-based TP of INR200 for FY28.

### Exhibit 11: Valuation methodology

Particulars		FY28
<b>Standalone EBITDA</b>	INRm	<b>2,230</b>
EV/EBIDTA Multiple	x	20
EV	INRm	45,050
Less: Standalone Net Debt	INRm	1,055
<b>Target Value</b>	INRm	<b>43,995</b>
<b>Carnations EBITDA (Management Contract)</b>	INRm	<b>1,203</b>
EV/EBIDTA Multiple	x	40
EV	INRm	48,598
<b>Fleur's EBITDA</b>	INRm	<b>5,828</b>
LemonTree's Share of Fleur EBITDA (58.91%)	INRm	3,433
EV/EBIDTA Multiple	x	20
EV	INRm	69,349
Less: LemonTree's Share of Fleur Net Debt	INRm	3,718
<b>Target Value</b>	INRm	<b>65,631</b>
Total Target Value	INRm	1,58,223
No. of shares	Mn	792
<b>Target Price</b>	INR	<b>200</b>

Source: MOFSL

### Exhibit 12: Revisions to our estimates

Earnings Change (INR m)	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	14,437	16,285	17,499	14,523	16,690	17,929	1%	2%	2%
EBITDA	6,983	8,363	9,108	7,011	8,506	9,261	0%	2%	2%
Adj. PAT	2,620	3,371	3,977	2,655	3,416	4,049	1%	1%	2%

Source: MOFSL

## Financials and valuations

Consolidated - Income Statement								(INRm)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>6,694</b>	<b>2,517</b>	<b>4,022</b>	<b>8,750</b>	<b>10,655</b>	<b>12,861</b>	<b>14,523</b>	<b>16,690</b>	<b>17,929</b>
Change (%)	21.8	-62.4	59.8	117.5	21.8	20.7	12.9	14.9	7.4
F&B Consumed	570	178	279	499	628	762	883	968	1,040
Employees Cost	1,553	704	973	1,497	1,878	2,185	2,419	2,620	2,815
Other Expenses	2,137	1,022	1,432	2,230	2,973	3,573	4,209	4,596	4,813
<b>Total Expenditure</b>	<b>4,260</b>	<b>1,905</b>	<b>2,683</b>	<b>4,226</b>	<b>5,479</b>	<b>6,520</b>	<b>7,512</b>	<b>8,184</b>	<b>8,668</b>
% of Sales	63.6	75.7	66.7	48.3	51.4	50.7	51.7	49.0	48.3
<b>EBITDA</b>	<b>2,434</b>	<b>613</b>	<b>1,339</b>	<b>4,524</b>	<b>5,176</b>	<b>6,341</b>	<b>7,011</b>	<b>8,506</b>	<b>9,261</b>
Margin (%)	36.4	24.3	33.3	51.7	48.6	49.3	48.3	51.0	51.7
Depreciation	922	1,076	1,043	966	1,121	1,393	1,395	1,434	1,450
<b>EBIT</b>	<b>1,512</b>	<b>-463</b>	<b>296</b>	<b>3,557</b>	<b>4,054</b>	<b>4,948</b>	<b>5,616</b>	<b>7,073</b>	<b>7,810</b>
Int. and Finance Charges	1,565	1,817	1,740	1,772	2,016	2,007	1,647	1,379	1,022
Other Income	58	133	140	36	113	23	61	67	72
<b>PBT bef. EO Exp.</b>	<b>5</b>	<b>-2,147</b>	<b>-1,304</b>	<b>1,822</b>	<b>2,151</b>	<b>2,965</b>	<b>4,031</b>	<b>5,760</b>	<b>6,860</b>
EO Items	0	0	153	-48	0	0	313	0	0
<b>PBT after EO Exp.</b>	<b>5</b>	<b>-2,147</b>	<b>-1,456</b>	<b>1,774</b>	<b>2,151</b>	<b>2,965</b>	<b>3,718</b>	<b>5,760</b>	<b>6,860</b>
Total Tax	109	-322	-72	377	341	531	682	1,325	1,578
Tax Rate (%)	2220.8	15.0	5.0	21.3	15.9	17.9	18.3	23.0	23.0
MI/ share of profit from associates	-9	-555	-510	251	325	468	615	1,019	1,233
<b>Reported PAT</b>	<b>-95</b>	<b>-1,271</b>	<b>-874</b>	<b>1,146</b>	<b>1,485</b>	<b>1,966</b>	<b>2,420</b>	<b>3,416</b>	<b>4,049</b>
<b>Adjusted PAT</b>	<b>-95</b>	<b>-1,271</b>	<b>-760</b>	<b>1,182</b>	<b>1,485</b>	<b>1,966</b>	<b>2,655</b>	<b>3,416</b>	<b>4,049</b>
Change (%)	-118.0	1,232.4	-40.2	-255.5	25.7	32.4	35.1	28.7	18.5
Margin (%)	-1.4	-50.5	-18.9	13.5	13.9	15.3	18.3	20.5	22.6

Consolidated - Balance Sheet								(INR M)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	7,903	7,904	7,908	7,916	7,918	7,918	7,918	7,918	7,918
Eq. Share Warrants & App. Money	0	0	0	0	0	0	0	0	0
Preference Capital	0	0	0	0	0	0	0	0	0
Total Reserves	1,986	1,272	404	621	1,750	3,716	6,137	9,553	13,602
<b>Net Worth</b>	<b>9,889</b>	<b>9,176</b>	<b>8,312</b>	<b>8,537</b>	<b>9,669</b>	<b>11,635</b>	<b>14,055</b>	<b>17,471</b>	<b>21,520</b>
Minority Interest	5,559	6,174	5,676	5,597	5,795	6,261	6,874	7,891	9,122
Total Loans	15,775	16,850	16,986	17,457	18,891	16,986	13,986	9,986	5,486
Lease Liability	4,619	4,671	4,247	4,253	4,423	4,431	4,431	4,431	4,431
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
<b>Capital Employed</b>	<b>35,841</b>	<b>36,870</b>	<b>35,223</b>	<b>35,844</b>	<b>38,779</b>	<b>39,313</b>	<b>39,346</b>	<b>39,779</b>	<b>40,559</b>
Gross Block	35,073	35,016	34,637	34,666	42,627	43,170	43,983	44,325	46,325
Less: Accum. Deprn.	2,977	4,052	5,096	6,062	7,183	8,576	9,971	11,404	12,855
<b>Net Fixed Assets</b>	<b>32,097</b>	<b>30,964</b>	<b>29,542</b>	<b>28,605</b>	<b>35,444</b>	<b>34,594</b>	<b>34,012</b>	<b>32,921</b>	<b>33,470</b>
Goodwill on Consolidation	951	951	951	951	951	951	951	951	951
Capital WIP	1,896	2,418	2,968	4,822	254	454	1,141	2,191	2,191
<b>Total Investments</b>	<b>164</b>	<b>79</b>	<b>114</b>	<b>73</b>	<b>151</b>	<b>446</b>	<b>446</b>	<b>446</b>	<b>446</b>
Current Investment	44	91	59	10	81	386	0	0	0
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>2,521</b>	<b>3,737</b>	<b>2,776</b>	<b>2,873</b>	<b>3,531</b>	<b>4,373</b>	<b>4,595</b>	<b>5,291</b>	<b>5,659</b>
Inventory	82	72	81	105	138	138	165	179	190
Account Receivables	503	308	291	560	715	786	875	1,006	1,081
Cash and Bank Balance	408	1,411	543	275	537	807	577	684	713
Loans and Advances	1,528	1,945	1,861	1,933	2,140	2,642	2,977	3,422	3,675
<b>Curr. Liability &amp; Prov.</b>	<b>1,786</b>	<b>1,278</b>	<b>1,128</b>	<b>1,479</b>	<b>1,552</b>	<b>1,505</b>	<b>1,799</b>	<b>2,020</b>	<b>2,157</b>
Account Payables	842	788	585	668	859	616	782	852	902
Other Current Liabilities	877	412	319	730	601	790	871	1,001	1,076
Provisions	67	78	224	81	92	99	145	167	179
<b>Net Current Assets</b>	<b>734</b>	<b>2,459</b>	<b>1,648</b>	<b>1,394</b>	<b>1,979</b>	<b>2,868</b>	<b>2,796</b>	<b>3,271</b>	<b>3,502</b>
Misc Expenditure	0	0	0	0	0	0	0	0	0
<b>Appl. of Funds</b>	<b>35,841</b>	<b>36,870</b>	<b>35,223</b>	<b>35,844</b>	<b>38,779</b>	<b>39,313</b>	<b>39,346</b>	<b>39,779</b>	<b>40,560</b>

## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>									
<b>EPS</b>	<b>-0.1</b>	<b>-1.6</b>	<b>-1.0</b>	<b>1.5</b>	<b>1.9</b>	<b>2.5</b>	<b>3.4</b>	<b>4.3</b>	<b>5.1</b>
Cash EPS	1.0	-0.2	0.4	2.7	3.3	4.2	5.1	6.1	6.9
BV/Share	12.5	11.6	10.5	10.8	12.2	14.7	17.7	22.1	27.2
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Valuation (x)</b>									
P/E	-1,103	-83	-138	89	71	54	40	31	26
Cash P/E	127.2	-539.1	371.1	49.0	40.4	31.3	26.0	21.7	19.1
P/BV	10.6	11.5	12.7	12.3	10.9	9.0	7.5	6.0	4.9
EV/Sales	18.8	50.3	31.6	14.6	12.1	9.9	8.6	7.3	6.6
EV/EBITDA	51.8	206.8	95.0	28.3	25.0	20.1	17.9	14.4	12.9
EV/Room (INRm)	29.6	29.8	29.9	26.5	26.8	26.4	26.0	25.4	24.2
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	-9.4	-1.5	0.9	2.8	1.6	5.7	6.3	8.1	8.5
<b>Return Ratios (%)</b>									
RoE	-1.0	-13.3	-8.7	14.0	16.3	18.5	20.7	21.7	20.8
RoCE	4.5	-0.9	1.1	9.4	10.2	11.7	13.4	17.2	19.4
RoIC	4.4	-1.0	0.7	8.6	10.0	10.8	12.3	14.8	16.3
<b>Working Capital Ratios</b>									
Fixed Asset Turnover (x)	0.2	0.1	0.1	0.3	0.2	0.3	0.3	0.4	0.4
Asset Turnover (x)	0.2	0.1	0.1	0.2	0.3	0.3	0.4	0.4	0.4
Inventory (Days)	4	10	7	4	5	4	4	4	4
Debtor (Days)	27	45	26	23	24	22	22	22	22
Creditor (Days)	46	114	53	28	29	17	20	19	18
<b>Leverage Ratio (x)</b>									
Current Ratio	1.4	2.9	2.5	1.9	2.3	2.9	2.6	2.6	2.6
Interest Cover Ratio	1.0	-0.3	0.2	2.0	2.0	2.5	3.4	5.1	7.6
Net Debt/Equity	1.5	1.7	2.0	2.0	1.9	1.4	0.9	0.5	0.2

### Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	5	-2,147	-1,446	1,782	2,151	2,962	4,031	5,760	6,860
Depreciation	922	1,076	1,043	966	1,121	1,393	1,395	1,434	1,450
Interest & Finance Charges	1,507	1,685	1,786	1,773	1,903	2,041	1,585	1,312	950
Direct Taxes Paid	-109	322	-17	-207	-341	-502	-682	-1,325	-1,578
(Inc)/Dec in WC	-754	-1,009	27	-403	-523	-416	-157	-368	-202
<b>CF from Operations</b>	<b>1,572</b>	<b>-74</b>	<b>1,394</b>	<b>3,912</b>	<b>4,312</b>	<b>5,478</b>	<b>6,172</b>	<b>6,813</b>	<b>7,481</b>
Others	-62	-635	-41	-63	339	-63	296	1,015	1,229
<b>CF from Operating incl EO</b>	<b>1,510</b>	<b>-709</b>	<b>1,353</b>	<b>3,849</b>	<b>4,651</b>	<b>5,416</b>	<b>6,469</b>	<b>7,828</b>	<b>8,710</b>
(Inc)/Dec in FA	-8,969	-465	-668	-1,618	-3,393	-932	-1,500	-1,392	-2,000
<b>Free Cash Flow</b>	<b>-7,459</b>	<b>-1,174</b>	<b>685</b>	<b>2,231</b>	<b>1,258</b>	<b>4,484</b>	<b>4,969</b>	<b>6,436</b>	<b>6,710</b>
(Pur)/Sale of Investments	210	85	132	8	-78	-357	0	0	0
Others	2,677	-276	-56	-1,222	-495	14	61	67	72
<b>CF from Investments</b>	<b>-6,082</b>	<b>-656</b>	<b>-591</b>	<b>-2,832</b>	<b>-3,965</b>	<b>-1,274</b>	<b>-1,439</b>	<b>-1,325</b>	<b>-1,928</b>
Issue of Shares	10	1,750	8	17	2	0	0	0	0
Inc/(Dec) in Debt	3,733	1,075	134	471	1,434	-1,927	-3,000	-4,000	-4,500
Interest Paid	-1,565	-1,817	-1,400	-1,432	-2,016	-1,593	-1,647	-1,379	-1,022
Dividend Paid	0	0	0	0	0	0	0	0	0
Others	2,488	1,361	-372	-379	157	-352	-613	-1,017	-1,231
<b>CF from Fin. Activity</b>	<b>4,667</b>	<b>2,368</b>	<b>-1,630</b>	<b>-1,323</b>	<b>-423</b>	<b>-3,872</b>	<b>-5,259</b>	<b>-6,396</b>	<b>-6,753</b>
<b>Inc/Dec of Cash</b>	<b>94</b>	<b>1,003</b>	<b>-869</b>	<b>-306</b>	<b>263</b>	<b>269</b>	<b>-229</b>	<b>107</b>	<b>29</b>
Opening Balance	314	408	1,411	543	275	537	807	577	684
<b>Closing Balance</b>	<b>408</b>	<b>1,411</b>	<b>543</b>	<b>275</b>	<b>537</b>	<b>807</b>	<b>577</b>	<b>684</b>	<b>713</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email

Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX), CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.